{"id":"NCT03920215","sponsor":"Oyster Point Pharma, Inc.","briefTitle":"Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease","officialTitle":"Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The ONSET Study)-Long Term Safety Follow-up","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2018-08-15","primaryCompletion":"2019-09-20","completion":"2019-09-20","firstPosted":"2019-04-18","resultsPosted":"2021-11-22","lastUpdate":"2023-11-01"},"enrollment":101,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Long Term Follow up Dry Eye Disease"],"interventions":[{"type":"DRUG","name":"OC-01 Low Dose, 0.12 mg/mL","otherNames":["OC-01 (varenicline) nasal spray, 0.12 mg/ml"]},{"type":"DRUG","name":"OC-01 Mid Dose, 0.6 mg/mL","otherNames":[]},{"type":"DRUG","name":"OC-01 High Dose, 1.2 mg/mL","otherNames":["OC-01 Mid Dose, 1.2 mg/mL"]},{"type":"DRUG","name":"Placebo (vehicle) nasal spray","otherNames":[]}],"arms":[{"label":"OC-01 Low Dose, 0.12 mg/mL","type":"ACTIVE_COMPARATOR"},{"label":"OC-01 Mid Dose, 0.6 mg/mL","type":"ACTIVE_COMPARATOR"},{"label":"OC-01 High Dose, 1.2 mg/mL","type":"ACTIVE_COMPARATOR"},{"label":"Placebo (vehicle) nasal spray","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this safety long-term follow-up study was to evaluate the safety of OC-01 Nasal Spray at 6 months and 12 months post treatment in the OPP-002 study (NCT03636061).","primaryOutcome":{"measure":"Number of Participants With the Left Nostril/Abnormal at 6 Months as Assessed by Intranasal Examinations","timeFrame":"6 months after the first treatment of OC-01 nasal spray/placebo in the OPP-002 study (Visit 1 OPP-002 and 6 months)","effectByArm":[{"arm":"OC-01 Low Dose, 0.12 mg/mL","deltaMin":0,"sd":null},{"arm":"OC-01 Mid Dose, 0.6 mg/mL","deltaMin":0,"sd":null},{"arm":"OC-01 High Dose, 1.2 mg/mL","deltaMin":0,"sd":null},{"arm":"Placebo (Vehicle) Nasal Spray","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"22 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":["Conjunctival oedema","Pain","Nasopharyngitis","Cataract","Conjunctival hyperaemia"]}}